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Abstract
On Reunion Island, in response to the threat of emergence of the pandemic influenza A(H1N1)2009 virus, we implemented enhanced influ-
enza surveillance from May 2009 onwards in order to detect the introduction of pandemic H1N1 influenza and to monitor its spread and
impact on public health. The first 2009 pandemic influenza A(H1N1) virus was identified in Re´union on July 5, 2009, in a traveller returning
from Australia; seasonal influenza B virus activity had already been detected. By the end of July, a sustained community pandemic virus trans-
mission had been established. Pandemic H1N1 influenza activity peaked during week 35 (24–30 August 2009), 4 weeks after the beginning
of the epidemic. The epidemic ended on week 38 and had lasted 9 weeks. During these 9 weeks, an estimated 66 915 persons who con-
sulted a physician could have been infected by the influenza A(H1N1)2009 virus, giving a cumulative attack rate for consultants of 8.26%.
Taking into account the people who did not consult, the total number of infected persons reached 104 067, giving a cumulative attack rate
for symptomatics of 12.85%. The crude fatality rate (CFR) for influenza A(H1N1)2009 and the CFR for acute respiratory infection was 0.7/
10 000 cases. Our data show that influenza pandemic did not have a health impact on overall mortality on Re´union Island. These findings
demonstrate the value of an integrated epidemiological, virological and hospital surveillance programme to monitor the scope of an epi-
demic, identify circulating strains and provide some guidance to public health control measures.
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Introduction
Following its emergence in March 2009 [1], the pandemic
A(H1N1) virus spread rapidly throughout the world, leading
to the declaration of an influenza pandemic by the World
Health Organization (WHO) on 11 June 2009 [2]. The
pandemic A(H1N1) virus was first detected in April in the
USA [3] and was shown to be responsible for outbreaks in
Mexico in March and April [4,5]. As of 27 November 2009,
worldwide more than 207 countries and overseas territories
or communities had reported laboratory confirmed cases of
pandemic influenza H1N1 2009, including over 7820 deaths
[6]. In the Southern hemisphere, the emergence of pandemic
H1N1 influenza coincided with the winter seasonal influenza
activity which began to increase in June 2009. Pandemic
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A(H1N1) activity increased rapidly in many of these coun-
tries and activity peaked in July in some regions, falling to
low levels by August or September in South Africa, Brazil,
Peru, Australia, and New Zealand [7–11]. In some other
southern hemisphere tropical areas in the Americas and
Asia, the pandemic A(H1N1) influenza virus was still circulat-
ing in September in some places.
Re´union island, a French overseas territory with 810 000
inhabitants (2009 estimate), is located in the southern
hemisphere in the South-Western Indian Ocean. It is 700 km
East of Madagascar and 200 km South-West of Mauritius, at
a longitude of 553 East and latitude of 215 South, above
the Tropic of Capricorn. Re´union has a health care system
similar to continental France. Although acute respiratory ill-
ness activity has been monitored continuously since 1996,
the circulation of influenza virus strains remains poorly docu-
mented. However, results of past monitoring suggest that
influenza activity increases annually in June–July. The last
reported influenza epidemic occurred in August–October
2007. Although the island is mainly exposed to seasonal influ-
enza from the Southern hemisphere, one-third of the annual
cases of influenza are reported during the northern hemi-
sphere’s influenza season between October and May. This
could be explained by the links with continental France as
approximately 2000 people travel each day between France
and Re´union.
In response to the threat of emergence and spread of
the pandemic influenza A(H1N1)2009 virus, the Regional
Office (Cire Re´union-Mayotte) of the French Institute for
Public Health Surveillance (Institut de veille sanitaire, InVS)
on Re´union Island implemented an enhanced influenza sur-
veillance from May 2009 onwards in order to detect the
introduction of the pandemic H1N1 influenza and to moni-
tor its spread and impact on public health [12,13]. This
report summarizes the results of this surveillance and
describes the dynamics and impact of the influenza pan-
demic on Re´union Island and the characteristics of labora-
tory-confirmed cases, including hospitalized, severe and fatal
cases.
Methods
On Re´union Island, the enhanced influenza surveillance pro-
gramme, set up in May 2009 [12], was modified after evi-
dence of local transmission and rapid spread of the 2009
pandemic H1N1 influenza virus. We describe the new sur-
veillance procedure started on 23 July which was based on a
range of indicators available from the surveillance systems
implemented before the emergence of the epidemic.
Virological surveillance
Virological surveillance was implemented in order to identify
and characterize circulating influenza viruses during the win-
ter season in Re´union Island. Specimens were collected by
sentinel and emergency department practitioners. Nasal
swabs were performed weekly by sentinel practitioners and
daily on every first adult and paediatric patient attendance in
the hospital emergency departments. In-patients with acute
respiratory infections (ARIs) were also surveyed. Specimens
were tested for both influenza virus A and B by a reverse-
transcriptase-polymerase-chain-reaction (RT-PCR) assay. The
2009 pandemic influenza A (H1N1) was confirmed by means
of a RT-PCR assay performed according to published guide-
lines from the US CDC. The 2009 H1N1 virus testing was
conducted in local laboratories and confirmed by the
National Reference Centre for Influenza (Institut Pasteur,
Paris). The RT-PCR assay was performed using a Super-
script One-Step RT-PCR with a Platinum Taq kit. (Invitro-
gen, Carlsbad, CA, USA). A specific RT-PCR for novel
influenza A(H1N1) was performed when positive virus A
specimens were identified.
Surveillance of ARI by the sentinel practitioner network
A sentinel practitioner network, comprising 23 general prac-
titioners and three paediatricians, covering all the island and
representing respectively, 3% and 10% of all private physi-
cians for each speciality, was in charge of the prospective
influenza surveillance. These physicians reported weekly the
number of ARIs and the total number of consultations. They
reported the percentage of consultations for ARI symptoms
with the following case definition: sudden onset of fever
>38C AND (cough OR breathing difficulty). Every physician
was expected to perform a nasal swab on the first two
patients of the week presenting with ARI symptoms with an
onset of <48 h. Weekly ARI consultation rates were com-
pared with rates for the same periods in the past 5 years
(2004–2008).
Surveillance of hospitalized patients and those with severe
disease
Hospitalized patients with laboratory confirmed
A(H1N1)2009 virus were reported by clinicians to the
Regional Office of InVS. A standardized form was used for
collecting epidemiologic, demographic and clinical data. A
hospitalized patient was defined as one with a laboratory-
confirmed influenza A(H1N1)2009 virus infection admitted
for more than 24 h to a medical ward. A severe case was
defined as a person with a laboratory-confirmed influenza
A(H1N1) 2009 virus infection who was admitted to an inten-
sive care unit (ICU) or who died.
310 Clinical Microbiology and Infection, Volume 16 Number 4, April 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 309–316
Mortality surveillance
An analysis of all death certificates received by the Regional
Public Health Authority was conducted. All certificates men-
tioning ‘Influenza’ were recorded as an influenza-associated
death. Electronic death certification was also used by the
Intensive Care Department of Saint-Denis hospital and ana-
lysed in real time by the Regional Office of InVS. In addition,
the National Institute for Statistics (Institut National de la
Statistique et des Etudes E´conomiques, Insee) recorded
deaths from all causes in France. For several years, Insee has
been monitoring and centralizing daily mortality in France,
including Re´union and the other French overseas territories.
This mortality was assessed using a real-time process. To
assess the affect of the pandemic virus outbreak on mortal-
ity, we compared the number of deaths observed during the
outbreak period with the expected number computed from
the 2005–2008 historical data. We analysed the period from
January 1, 2005, to October 4, 2009, but excluding the year
2006 because of the chikungunya epidemic at that time. The
expected number of deaths (all causes) for 2009 was the
number of deaths by age observed during 2005–2008 (except
2006) modified by an estimate of the population size for the
period. Details of this method, which was used during the
heat wave in France in 2003, have already been described
[14]. The number of deaths in Re´union was obtained daily
from 13 of 24 computerized registry offices throughout the
island which represented 87% of the deaths. A preliminary
study had validated this surveillance system [15].
Estimates of the number of cases
Since week 30, the number of patients consulting for pan-
demic influenza A (H1N1) was estimated from data from the
sentinel practitioner network. The number of ARIs was
extrapolated from the entire medical activity on Re´union
Island by using the total number of consultations provided by
the social insurance data for the week studied. The number
of consultations with a A(H1N1) 2009 infection was calcu-
lated by applying the proportion of positivity for each week
obtained from a random sample of patients with ARI tested
by the sentinel practitioners to the total estimated number
of patients with ARI in the same week.
Cross-sectional study
A cross-sectional survey designed by the Regional Office of
InVS was conducted by the Louis Harris Institute in order to
assess the prevalence of ARI amongst the general population
and particularly in persons who did not consult a physician.
This survey was conducted by telephone interviewing
between 7 and 14 October 2009 among a representative
sample of 420 persons living on Re´union Island.
Statistical analysis
We performed statistical analysis using Epidata Analysis and
STATA 9.0 software. We calculated descriptive statistics
for all study variables. We report data for continuous vari-
ables as median and for categorical variables as percentage
(with 95% confidence intervals, where appropriate). Chi-
square tests or Fisher-exact tests were used when appropri-
ate to compare categorical variables, and the Student test or
the Mann-Whitney test used when appropriate to compare
continuous variables.
Results
Virologic analysis (Fig. 1)
During the austral winter 2009, Influenza B virus was first
detected on week 23 (starting 1 June) and was the only influ-
enza strain detected during the following 3 weeks. A very
small proportion of A(H3N2) viruses were detected in
weeks 30–32 and week 35. Influenza A(H1N1)2009 was first
detected on 5 July (week 27). Between week 27 and week
41 (starting 5 October), influenza A(H1N1)2009 viruses
were detected by RT-PCR in 785 of 2229 nasal swabs (a
35.2% positivity rate). In week 31 (starting 27 July), the pan-
demic virus became the dominant circulating strain on the
Island and reached a 95% positivity rate in week 34. We also
identified 16 persons co-infected with both the pandemic
virus and the influenza B virus.
Dynamics of the epidemic (Fig. 2)
From week 23 (starting 1 June) to week 30 (starting July
20) the weekly ARI consultation rates remained below the
2004–2008 mean rates. On 5 July 2009 (week 27), when
seasonal influenza was already reported on the island, the
first imported case of pandemic H1N1 influenza was
detected in a traveller returning from Australia. From
week 27 to week 30, no evidence of local transmission of
pandemic H1N1 influenza was detected and all laboratory-
confirmed cases were considered as imported or having an
epidemiological link with another imported laboratory-
confirmed case. On 22 July, the first autochthonous case
was reported. From week 30, there was evidence of local
transmission and the individual surveillance was shifted to a
population-based surveillance. Then, on week 31, the ARI
rate exceeded the 2004–2008 mean and increased sharply
until week 35 (starting 24 August). During this peak week,
ARI cases represented 20.6% of consultations reported by
sentinel practitioners. This was the highest rate observed
in Re´union during the previous 5 years of influenza sur-
veillance and 65% of nasal swabs performed by sentinel
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network physicians were positive for A(H1N1)2009. During
the 9-week epidemic period (week 30–38), the number of
cases of patients with A (H1N1) 2009 infections who con-
sulted a physician was estimated at 66 915. During the
peak week (week 35), an estimated 18 473 [CI 95%:
12 447–24 404] persons were infected by the pandemic
virus. At the end of the epidemic (week 38), the estimated
cumulative attack rate for symptomatic persons who con-
sulted was 8.26%. In the cross-sectional study, 28.5% of
the people questioned reported symptoms of ARI during
the period. Among these, 35.7% did not consult a physi-
cian. Using this proportion of symptomatic people who did
not consult, an estimate of 104 067 infected persons was
made. Therefore, the final cumulative attack rate for symp-
tomatic people was 12.85%.
Laboratory-Confirmed Cases of Influenza
A(H1N1)2009
Characteristics and symptoms of patients (Table 1)
From 5 July through 18 October, a total of 785 confirmed
cases of patients infected by influenza A(H1N1)2009 virus
were reported to the Regional office of InVS. The sex
ratio M/F was 0.7 and the median age was 17.7 years.
A total of 67.5% of patients were between the ages of
5 and 50 years and 24% were <5 years old. The most
common symptoms were fever (91%), cough (88%), coryza
(63%), fatigue (52%) and sore throat (49%). In addition,
18% of patients had vomiting and 8% had diar-
rhoea. Among 330 patients for whom treatment status
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FIG. 1. Estimate of the number of consulta-
tions for patients with ARI infected with the
influenza A(H1N1)2009 virus and the confi-
dence interval (CI), Re´union Island, 2009.
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was known, 218 (66%) received oseltamivir. Seasonal influ-
enza vaccinations in 2008 were reported by 19/681
patients (2.8%). Co-infection with influenza B virus was
diagnosed in 16 patients. Forty-nine cases were pregnant
women. Of 42 for whom hospitalization status was known,
21 (50%) were hospitalized, including one in an ICU.
Among 40 pregnant women for whom the underlying
medical condition was known, three (7.5%) had other
co-morbidities.
Hospitalized patients (Table 2)
Of the 653 patients with confirmed influenza A(H1N1)2009
infection for whom hospitalization status was known, 282
(43%) required hospitalization. The median age of these
patients was 18.9 years (range, 2 months to 89 years). The
median time from the onset of illness to hospital admission
was 1 day (range, 0–17 days). Of the 180 patients for whom
the underlying medical condition was known, 117 (65%) had
at least one condition, including 54% of children <18 years
TABLE 1. Characteristics, symp-
toms and underlying medical con-
ditions of the 785 patients with
laboratory-confirmed A(H1N1)2009
virus, Re´union Island, 2009
Characteristics
A(H1N1)2009
(n = 785) N (%)
Seasonal B
(n = 119) N (%) p-Value
Sex
Male 310/785 (39.5) 45/119 (37.8) 0.73
Female 471/785 (60.5) 74/119 (62.2)
Age
Median (Range) 17.3 (1 month–89
years-old)
19.9 (2 months–62
years-old)
0.049
Age groups
0–23 months 125/776 (16.1) 12/114 (10.5) <0.001
2–4 years-old 62/776 (8) 29/114 (25.4)
5–18 years-old 229/776 (29.5) 70/114 (61.4)
19–50 years-old 295/776 (38) 3/114 (2.6)
>50 years-old 65/776 (8.4) 0/114 (0)
Clinical signs
Fever 684/755 (90.6) 104/117 (88.9) NS
Cough 662/756 (87.6) 100/117 (85.5) NS
Rhinorrhoea 479/756 (63.4) 90/117 (76.9) 0.004
Asthenia 396/756 (52.4) 74/117 (63.2) 0.03
Pharyngitis 373/756 (49.3) 63/117 (53.8) NS
Myalgia 348/756 (46) 70/117 (59.8) 0.005
Headache 297/756 (39.3) 58/117 (49.6) 0.03
Shortness of breath 205/756 (27.1) 23/117 (19.7) NS
Arthralgia 205/756 (27.1) 43/117 (36.8) 0.03
Vomiting 139/756 (18.4) 21/117 (17.9) NS
Abdominal pain 103/756 (13.6) 9/117 (7.7) 0.07
Conjunctivitis 97/756 (12.8) 23/117 (19.7) 0.04
Diarrhoea 60/756 (7.9) 5/117 (4.3) NS
Adenopathy 52/756 (6.9) 7/117 (6.0) NS
Risk factors
Children <1 year-old 57/260 (21.9) NA NA
Chronic respiratory disease 56/259 (21.6) NA NA
Pregnancy 48/267 (18) NA NA
Diabetes 24/259 (9.3) NA NA
Congenital heart disorder 11/259 (4.2) NA NA
Immunodeficiency 10/259 (3.9) NA NA
Obesity 9/269 (3.5) NA NA
Cardiac insufficiency or severe valvular disease 8/259 (3.1) NA NA
Cystic fibrosis 6/259 (2.3) NA NA
Nephrotic syndrome 5/259 (1.9) NA NA
Bronchopulmonary dysplasia 5/259 (1.5) NA NA
Sickle cell anaemia 3/259 (1.2) NA NA
Severity signs
Badly tolerated clinical symptoms 35/81 (43.2) NA NA
Co-infection (confirmed or suspected) 22/81 (27.2) NA NA
Acute respiratory distress syndrome 19/81 (23.5) NA NA
Pre-existing illness failure 11/81 (15.6) NA NA
Neurological complication 8/81 (9.9) NA NA
Cardiac complication 5/81 (6.2) NA NA
Under respiratory assistance 2/81 (2.5) NA NA
Multi-organ failure 1/81 (1.2) NA NA
Hospitalization
Hospitalized patients 282/653 (43.2) 22/91 (24.2) <0.001
Hospitalization in an intensive care unit 24/282 (8.5) 1/91 (1.1) 0.01
Severe casesa 25/282 (8.9) 1/91 (1.1) 0.01
Cured 17/25 1/1
Died 6/25 0/1
Still hospitalized 2/25 0/1
Curative treatment
Oseltamivir 208/327 (63.6) 24/35 (68.6) NS
NA, non applicable; NS, not significant.
aPatient who was admitted to an intensive care unit or died.
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and 46% of adults; 10.6% had at least two conditions. The
hospitalization rate for influenza A(H1N1)2009 was 30/
10 000 during the epidemic.
Severe and fatal cases (Table 2)
A total of 25 patients with severe infection (admission to an
ICU or death) were reported. Of the 282 hospitalized
patients, 24 (8.5%) were admitted to an intensive care unit
(ICU) and seven died (six in an ICU and one in a medical
ward). The median age of the 25 severe cases was 39.1 years
(range, 4 months to 78 years) and sex ratio M/F was 0.8. Of
the 25 severe cases, 19 (76%) had an underlying medical con-
dition. Of the 24 patients admitted to an ICU, 13 (54%) had
acute respiratory distress syndrome (ARDS), 15 required
mechanical ventilation and three required Extra Corporeal
Membrane Oxygenation (ECMO). Among these severe
patients, the median time from the onset of illness to the ini-
tiation of antiviral therapy was 8 days (range, 3–16 days).
The hospitalization rate in an ICU (n = 24) using the esti-
mated total number of persons infected with A(H1N1)2009
virus as denominator (n = 104,067) was 2.3/10 000.
Of the 282 hospitalized patients, seven (2.5%) with a labora-
tory-confirmed influenza A(H1N1)2009 virus infection died.
Six had been admitted to an ICU and required mechanical ven-
tilation, including two who required ECMO. The median age
of the seven fatal cases was 32 years (range, 5–78 years).
They included four women (5, 18, 28 and 78 years old)
and three men (32, 54 and 69 years old). Six of these
patients presented with an underlying medical condition,
including chronic cardiac insufficiency (n = 3), chronic respi-
ratory disease (n = 2), diabetes mellitus (n = 2), malignant
haemopathy (n = 1) and congenital encephalopathy (n = 1).
The seventh patient was a 32-year-old man with no identified
underlying medical condition who had chronic alcohol con-
sumption without liver dysfunction. The median time from
the onset of illness to death was 16.5 days (range, 7–75).
TABLE 2. Characteristics of hospi-
talized patients who were not
admitted to an intensive care unit
(ICU) and survived and patients
who were admitted to an ICU or
died, Re´union Island, 2009
Characteristics
Patients who were
not admitted to an
ICU and survived
(n = 258) N (%)
Patients who
were admitted
to an ICU or died
(n = 25) N (%) p-Value
Sex
Male 94/258 (36.4) 11/25 (44) 0.45
Female 164/258 (63.6) 14/25 (56)
Age
Median (Range) 17.9 (2 months- 89
years-old)
39.1 (4 months- 78
years-old)
<0.001
Age groups
0–23 months 64/258 (24.8) 2/25 (8) 0.005
2–4 years-old 15/258 (5.8) 0/25 (0)
5–18 years-old 55/258 (21.3) 6/25 (24)
19–50 years-old 89/258 (34.5) 7/25 (28)
>50 years-old 35/258 (13.6) 10/25 (40)
Risk factors
Children <1 year-old 31/108 (28.7) 1/25 (4) 0.01
Pregnancy 20/110 (18.1) 1/25 (4) NS
Asthma or Chronic respiratory disease 17/108 (15.7) 10/25 (40) 0.01
Diabetes 13/108 (12) 4/25 (16) NS
Congenital heart disorder 6/108 (5.55) 0/25 (0) NS
Cardiac insufficiency or severe
valvular disease
5/108 (4.6) 4/25 (16) NS
Immunodeficiency 4/108 (3.7) 1/25 (4) NS
Obesity 3/108 (2.7) 1/25 (4) NS
Bronchopulmonary dysplasia 2/108 (1.85) 0/25 (0) NS
Sickle cell anaemia 2/108 (1.85) 0/25 (0) NS
Nephrotic syndrome 1/108 (0.9) 0/25 (0) NS
Others 12/108 (11.1) 10/25 (40)a NA
Severity signs
Badly tolerated clinical symptoms 23/58 (39.6) 25/25 (100) NA
Co-infection (confirmed or suspected) 13/58 (22.4) 11/25 (44) 0.047
Acute respiratory distress syndrome 11/58 (19) 17/25 (68) <0.001
Pre-existing illness failure 7/58 (12.1) 11/25 (44) 0.003
Neurological complication 7/58 (12.1) 4/25 (16) NS
Cardiac complication 3/58 (5.2) 3/25 (12) NS
Under respiratory assistance 1/58 (1.7) 8/25 (32) 0
Multi-organ failure 0/58 (0) 4/25 (16) 0.01
Others 10/58 (17.2) 2/25 (4)b NA
Antiviral treatment
Any 73/152 (48) 19/19 (100)
£2 days after onset of symptoms 39/144 (27.1) 0/19 (0)
Days (median) from onset of
symptoms to initiation (Range)
1 (0–34) 8 (3–16 days) <0.001
NA, non applicable; NS, not significant.
aChronic high blood pressure (n = 7), encephalopathy (n = 2), Hodgkin’s disease (n = 1), adrenal insufficiency (n = 1),
epilepsy (n = 1).
bEncephalitis (n = 1), disseminated intravascular coagulation (n = 1).
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Lethality and mortality
Using these seven laboratory-confirmed influenza
A(H1N1)2009 deaths as numerator and the estimated total
number of A(H1N1)2009 influenza cases as denominator,
the crude fatality rate (CFR) for influenza A(H1N1)2009 was
of 0.7/10 000 cases. In addition, health authorities received
seven other death certificates mentioning influenza with no
laboratory investigation. Using the total of 14 deaths as
numerator, the CFR for ARI was 0.7/10 000 cases.
During the study period in 2009, the weekly deaths
remained within the expected range of statistical variation. No
excess deaths were observed during the epidemic period
(week 30–38); the expected number of deaths was 669
whereas 611 deaths were reported. The weekly mean [range]
of observed deaths due to all causes was 68 [55–84] (standard
deviation 12) vs 74 [72–78] (SD 11) for expected deaths.
Discussion
The first 2009 pandemic influenza A(H1N1) virus was identified
on Re´union Island on 5 July 2009 in a traveller returning from
Australia; seasonal influenza B virus activity had already been
detected. By the end of July, a sustained community pandemic
virus transmission had been established. The pandemic virus
became the predominant circulating influenza virus on Re´union
within 4 weeks following its first detection. Pandemic H1N1
influenza activity peaked during week 35 (24–30 August),
4 weeks after the beginning of the epidemic. The epidemic
ended on week 38 and had lasted 9 weeks. During those
9 weeks, an estimated 66 915 persons who consulted a physi-
cian were infected by the influenza A(H1N1)2009 virus, giving a
cumulative attack rate of 8.26%. Taking into account those who
did not consult a physician, the total number of symptomatic
infected persons reached 104 067, giving a cumulative attack
rate of 12.85%. Our data show that the influenza A(H1N1)2009
outbreak had no impact on overall mortality on Re´union Island.
The epidemiological situation has also been well described
in other countries of southern hemisphere [16]. The 4-week
delay before the appearance of the pandemic virus was also
observed in New Zealand [11]. In South Africa, the first case
was detected on week 29 and the peak week was reached
on week 32, 3 weeks before the Re´union peak [7]. The pan-
demic appears to have been remarkably similar in Australia,
New Zealand and Re´union [11,17]. Despite considerable
geographical and demographical differences between them,
the pandemic showed a consistent pattern of infection across
these countries [16].
Our results showed that 67.5% of laboratory-confirmed
persons were between the age of 5 and 50 years and seem to
confirm observations of other studies [1]. The low number of
infected persons >50 years is consistent with the hypothesis
suggested in other studies that a persistent immunity could
protect older people. However, the high proportion of chil-
dren under 2 years in our study should be considered with
caution. Indeed, French authorities recommended special
attention to children presenting with ARI symptoms.
Data concerning the number of admissions of pregnant
women should also be interpreted with caution. Indeed,
health-care providers might be more likely to admit a preg-
nant woman than a non-pregnant one presenting with similar
symptoms, leading to an over representation of pregnant
women among hospitalized patients. However, unlike other
observations [18], a very limited number of pregnant women
were admitted to an ICU (1/24) and none died. This could
be explained by knowledge of the potential severity of the
disease during pregnancy and early management in hospital.
According to the WHO (conclusion of the meeting at the
headquarters of the Pan American Health Organization in
Washington, DC on 14–16 October 2009), the risk of
severe or fatal illness is highest in three groups: pregnant
women, especially during the third trimester of pregnancy,
children younger than 2 years of age, and people with
chronic lung disease, including asthma. Neurological disor-
ders can increase the risk of severe disease in children.
Although the exact role of obesity is poorly understood at
present, obesity and especially morbid obesity have been
present in a large portion of severe and fatal cases [19]. In
our study, vulnerable groups included mainly diabetic persons
and those with chronic respiratory disease, including asthma.
This could be explained by a relatively high asthma symptom
prevalence (21.5% on a 13–14 years population) [20] and a
high prevalence of type 2 diabetes (20%) [21] on Re´union
Island. On the other hand, our data showed a low propor-
tion of obesity in severely ill patients although a high preva-
lence of obesity has been described on Re´union Island [21].
In a large US case series of hospitalized patients with 2009
H1N1 virus infection, underlying medical conditions were
found in 67% of patients admitted to an ICU, including
asthma or chronic obstructive pulmonary disease (in 28%),
immunosuppression (in 18%) and neurological disease (in
18%) [22]. In our series, patients who were admitted to an
ICU and those who died were older and had a longer time
between the onset of illness and the initiation of antiviral
therapy compared with patients who were not admitted to
an ICU. These results confirm those of the US study [22].
The cumulative incidence of hospitalization and cumulative
incidence of death has shown wide variation by country in
the southern hemisphere [16]. The cumulative incidence of
hospitalization ranged from 2.0 to 31.8 per 100 000 of popu-
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lation, and the cumulative incidence of death ranged from 0
to 36.1 per million population. On Re´union, the definitive
cumulative incidence of hospitalization was 34.8/100 000 and
the mortality rate for A(H1N1) virus infection was 8.6/
1 000 000. A report from New Zealand estimated that
approximately 7.5% of the population had symptomatic ill-
ness, suggesting that 10–15% may have been infected with a
CFR <0.01%. On Re´union, a quite similar cumulative symp-
tomatic attack rate of 12.85% was seen with a CFR of 0.7/
10 000 cases. The impact of the pandemic in the Re´union
population has not been severe and hospitals and health care
centres have not been overwhelmed.
Re´union Island is also exposed to seasonal influenza from
the northern hemisphere because of its links with continental
France. Therefore, a second wave of A(H1N1) 2009 influ-
enza cannot be excluded following the pandemic wave
expected in northern hemisphere countries. Thus, ongoing
surveillance will continue to detect a second wave of the epi-
demic and to monitor and characterise potential virus
changes. These findings demonstrate the value of using an
integrated epidemiological, virological and hospital surveil-
lance programme in order to monitor the scope of an influ-
enza epidemic, identify circulating strains and provide some
guidance for public health control measures. These results
could provide relevant information for northern hemisphere
countries for their own management of their ongoing epi-
demic and control measures.
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